Inventors:
Jeffrey SUGARMAN - Santa Rosa CA, US
Assignee:
Dow Pharmaceutical Sciences - Petaluma CA
International Classification:
A61K 31/436, A61K 31/4164, A61K 31/194, A61K 31/65
Abstract:
The present application relates to methods of preventing or treating skin disorders exhibiting telangiectasia, for example, rosacea exhibiting an erythematotelangiectatic subtype. Exemplary methods comprise administering to a patient a formulation comprising a therapeutically effective amount of an mTOR inhibitor, such as rapamycin, wherein the mTOR inhibitor is the only active agent in the formulation. Suitably, the formulations are topical formulations administered to the face.